Journal of Clinical Oncology
Articles in this Issue
First-line (1L) olomorasib + pembrolizumab in patients with <i>KRAS</i> G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01.
8628 Background: For patients (pts) with 1L KRAS G12C-mutant advanced NSCLC and PD...
Insights into the impact of base-excision–repair genes on immunotherapy response in solid tumors.
e14548 Background: Base-excision repair (BER) is the primary pathway that removes ubiquitous single-base lesions from oxid...
When to begin? A chart-based review of advanced care planning in cancer patients one year prior to death.
e24043 Background: Timely goals of care (GOC) conversations are a critical component of high-quality oncologic care. Despi...
Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.
9500 Background: Intismeran is an mRNA-based individualized neoantigen therapy designed to increase endogenous neo...
Homologous recombination signature (HRDsig) in clinically advanced gallbladder adenocarcinoma (CAGAC): A genomic landscape study.
4138 Background: CAGAC is an aggressive malignancy with poor prognosis where chemotherapy and immunotherapy provide a limi...
Influence of oncogenic protein sequestration by platelets on early and stage-specific breast cancer detection.
e12601 Background: Mammography remains the standard modality for breast cancer (BC) screening but has several limitations....
National mortality trends in colorectal cancer patients with psychiatric and respiratory comorbidities in the United States,1999-2023: A CDC WONDER analysis.
e15660 Background: Colorectal Cancer (CRC) is a leading cause of cancer-related deaths in the United States. Comorbidities...
Functional domain disruption to define the molecular and clinical spectrum of germline <i>RAD51</i> family variants in hereditary breast cancer (BC).
572 Background: RAD51 paralogs (RAD51C, RAD51D, XRCC2) and RAD50 are crucial in DNA repair. Germline pathogenic variants (...
Evaluating physician perspectives on neoadjuvant immunotherapy and chemotherapy in early-stage triple-negative breast cancer.
e12633 Background: The Keynote-522 trial established neoadjuvant chemo-immunotherapy as a new standard of care for patient...
Evaluation of the impact of GLP-1 receptor agonists (RAs) on stage of PDAC diagnosis: A retrospective matched cohort study.
e16462 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is most frequently diagnosed a...
PRaG 5.0: Personalized thymosin alpha-1 and radioimmunotherapy for advanced refractory solid tumors—Data from an expanded cohort.
2516 Background: Treatment-related lymphopenia and inadequate anti-tumor immune activation remains major barriers to impro...
Phase II study of sintilimab combined with nab-paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer.
5560 Background: Platinum-resistant recurrent ovarian cancer (PROC) remains a major therapeutic challenge with limited eff...
Endocrine therapy recommendation after breast-conserving surgery for ER+ ductal carcinoma in-situ and impact on clinical outcomes.
e12619 Background: NCCN guidelines recommend consideration of 5 years of adjuvant endocrine therapy (ET) after breast cons...
Cadonilimab, a bispecific anti–PD-1/CTLA-4 antibody, for patients with dMMR/MSI-H metastatic colorectal cancer after progression on anti–PD-(L)1 therapy: A multicenter, single-arm, phase 2 trial (CSWOG-C03).
3577 Background: Immune checkpoint blockade targeting PD-1 is the standard of care for patients with mismatch repair–defic...
Small cell prostate cancer: Risks for metastatic disease.
e17036 Background: Small cell carcinoma of the prostate is a rare but highly aggressive subtype of prostate cancer, freque...
Time-toxicity of first-line systemic therapy for hepatocellular carcinoma in clinical practice.
4145 Background: Combination immunotherapy has become a standard first-line systemic treatment for hepatocellular carcinom...
Estimating individual benefit from adjuvant chemotherapy in hormone receptor–positive breast cancer using causal multimodal artificial intelligence.
551 Background: Adjuvant chemotherapy decisions in HR+/HER2– early breast cancer are often guided by prognostic gene expre...
Exploratory associations between incretin-based therapies and plasma cell disorders in patients with type 2 diabetes: A real-world study.
7571 Background: Incretin-based therapies, including dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-...
CARBON-SUSTAIN study: Visit-sparing, low-emission hypofractionated radiation therapy in a traffic-dense Indian megacity.
e23117 Background: In megacities, serial radiation therapy (RT) visits markedly augment healthcare-related carbon emission...
Comparative evaluation of targeted RNA sequencing and RNA-exome sequencing for fusion detection in soft tissue sarcomas.
e23524 Background: Soft tissue sarcomas are heterogeneous mesenchymal malignancies with overlapping histology, making diag...
Explainable AI to enable precision risk stratification for advanced melanoma in underrepresented Middle Eastern cohorts.
e21526 Background: Early identification of advanced-stage melanoma using baseline clinical and histopathological data coul...
Zopapogene imadenovec-drba, a novel non-replicating adenoviral vector-based immunotherapy: Effects on complete and durable responses in recurrent respiratory papillomatosis pivotal trial.
6104 Background: Recurrent respiratory papillomatosis (RRP) is a rare, neoplastic disorder caused by chronic human papillo...
Facilitators and barriers to Medicaid services for childhood cancer survivors: Perspectives from oncology providers and staff.
e22009 Background: Stable insurance coverage is critical for childhood cancer survivors who require lifelong medical care...
Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) plus tislelizumab (Tisle) combined with adjuvant tisle as a perioperative therapy for hepatocellular carcinoma (HCC) at high-risk of recurrence: A single-arm, phase II study.
e16284 Background: Adjuvant therapy alone after curative resection has failed to reduce recurrence or improve survival in...
Investigating the molecular characteristics underlying desmoid tumor clinical trajectory.
11583 Background: Desmoid tumors are locally aggressive mesenchymal neoplasms that primarily affect adolescents and young...